Home Page
An experienced guide to the world of finance
providing tools and information that help make
best financial decisions
My FinanceGates.com Register
 
Home  | News   |  Business News 
SEARCH
  News & Commentary
  News
  Reviews
  Columnist Articles
  RSS News
  Economy
  Economic Charts
  Financial Calendars
  Banking & Loans
  Loan Rates
  Deposit Rates
  Rate Alert
  Banking Top Rating
  Education
  Banking
  Investing
  Stock Brokerage
  Dictionary
  Financial Directory
  Banking
  Funds
  Insurance
  Stock Brokerage
  Billing
  My FinanceGates
  Register
  Sign In



Market News Insurance Billing
Banking Business News World News
Funds Brokerage

Friday April 08, 08:28
FDA’s decision hints Merck’s Vioxx has chances for comeback
(by Natali Novak)

 Send link to friend
FDA’s decision hints Merck’s Vioxx has chances for comeback On Thursday, the Food and Drug Administration (FDA) decided not to pull Celebrex out of the market despite suspicions of its link to cardiac cases. The decision cheered Merck & Co.’s investors hoping that its Vioxx would also soon return to the market.

The Food and Drug Administration for the first time since a February hearing admitted the possibility of Vioxx coming back to the marketplace saying the agency will "carefully review any proposal from Merck for resumption of marketing of Vioxx."

Vioxx, with Pfizer’s Bextra and Celebrex, belong to a class of pain relievers suspected to be linked with a number of heart attack and stroke incidences. Since 2004, the drugs were removed from the worldwide market.

Merck spokeswoman said yesterday that the company looked forward to discussions with the FDA over Vioxx but failed to confirm whether those talks already had started up.
Merck shares rose 1% closing at $33.49 on Thursday.

Since Vioxx’s removal, Merck has been involved in more than 600 lawsuits over its handling the drug’s withdrawal. Market analysts have forecast the risk for the company to face a $20 billion legal liability over Vioxx.

However, the analysts’ speculations about the chances of Vioxx to return to the market are going to the extremes.
All business news
Read the related news and articles:
28 Feb 2005 11:07 AM Idec and Biogen suspend Tysabri after patient death
28 Feb 2005 10:29 AM 10 FDA members who voted in favor of Bextra and Vioxx had ties with drug makers
22 Feb 2005 09:11 AM SUNTRUST ROBINSON HUMPHREY RAISED MERCK TO "BUY"
22 Feb 2005 08:50 AM Update 1: Vioxx to be put on markets again?
21 Feb 2005 08:36 AM FDA reviews its drug policy
 


   KEYWORD SEARCH

KEYWORDS:
   SUBSCRIPTION
Join FinanceGates.com mailing list and get news and financial advices on home finance, auto finance, insurances, funds, online payments and much more.
ABOUT US
PARTNERSHIP
ADVERTISING
LEGAL DISCLAIMER
PRIVACY POLICY
CONTACT US
LINKS
RSS NEWS


Copyright © FinanceGates.com - independent financial advice and personal finance advice, an InternetGates.com company, 2003-2008. All rights reserved.
Finance Gates provides personal finance advice on banking, insurance, investing and billing.
Reading materials of this site you can be sure that you get independent financial advice.